Phase 3 Trial Finds Daraxonrasib Doubles Median Survival to 7 Months in Advanced Pancreatic Cancer

# Phase 3 Trial Shows Daraxonrasib Doubles Median Survival in Metastatic Pancreatic Cancer Patients RevMed enrolled more than 500 patients with metastatic pancreatic ductal adenocarcinoma in a Phase 3 clinical trial for daraxonrasib. The trial involved patients whose previous treatments had failed.

Half of the participants received a daily oral dose of 300 mg daraxonrasib, while the other half were given standard-of-care intravenous chemotherapy.

2 months in the Phase 3 trial. 7 months. Daraxonrasib successfully achieved all of the main goals laid out in the Phase 3 clinical trial. RevMed said daraxonrasib was generally well tolerated in the late-stage trial.

RevMed said daraxonrasib had a manageable safety profile in the late-stage trial. No new issues were observed with daraxonrasib in the late-stage trial. RevMed plans to submit the trial results to the FDA.

RevMed seeks approval for daraxonrasib as a second-line treatment for patients whose cancer has already spread after prior therapy. Revolution Medicines was the first cancer drug developer to receive a Commissioner’s National Priority Voucher for a cancer therapy, which places daraxonrasib's application on an expedited review track.

Former Senator Ben Sasse Reports Tumor Reduction from Daraxonrasib Former Sen.

Ben Sasse represented Nebraska in the US Senate from 2015 to early 2023. Ben Sasse was diagnosed with Stage 4 pancreatic cancer last year. Doctors estimated Ben Sasse had three to four months to live upon diagnosis.

Ben Sasse's torso was full of tumors and the disease had spread throughout his body at diagnosis. Ben Sasse became a participant in a clinical trial for daraxonrasib. Daraxonrasib does not yet have FDA approval.

Ben Sasse is 54 years old. Ben Sasse has a wife and three children ages 24, 22, and 14. Ben Sasse told Stat News this week that daraxonrasib has reduced his tumor volume by about 60%. Ben Sasse told Stat News this week that his pain levels are way, way down.

Expert Views on Daraxonrasib's Mechanism and Pancreatic Cancer Challenges Dr.

Nicholas Hornstein is a medical oncologist at Northwell’s Lenox Hill Hospital. Dr. Nicholas Hornstein was not involved in the trial. Dr. " Daraxonrasib targets a mutated protein called KRAS in the body.

Dr. Nicholas Hornstein said KRAS acts like a stuck accelerator in cancer cells, telling them to keep growing when they should stop. Dr. Nicholas Hornstein said scientists have been trying to block KRAS for decades with little success.

Dr. Nicholas Hornstein said recent drugs have managed to target one specific faulty version of KRAS. Dr. Nicholas Hornstein said daraxonrasib appears to work across multiple versions of KRAS. A rash is a common side effect in patients taking daraxonrasib.

Dr. Nicholas Hornstein said skin toxicity like what Ben Sasse is experiencing is a relatively common side effect with cancer drugs designed to block KRAS activity. Dr. Nicholas Hornstein said the toxicity is generally far less than what Ben Sasse reported.

Dr. Nicholas Hornstein said involving onco-dermatology early and using some newer agents leads to significant success in mitigating these side effects. " Dr. Brian M. Wolpin is a professor of medicine at Harvard Medical School.

Dr. Brian M. Wolpin is the lead researcher for the Phase 3 daraxonrasib trial. Dr. Brian M. " Dr. Brian M.

Broader Context of Pancreatic Cancer Incidence and Outcomes Roughly 80% of PDAC patients are diagnosed at an advanced or metastatic stage.

About 90% of patients in advanced or metastatic PDAC cases have RAS mutations targeted by daraxonrasib. Metastatic PDAC has a five-year survival rate of 3%. Metastatic PDAC remains one of the leading causes of cancer-related deaths in the US.

An estimated 67,530 Americans will be diagnosed with pancreatic cancer in 2026. An estimated 52,740 Americans are expected to die from pancreatic cancer in 2026. RevMed is testing daraxonrasib on its own and in combination with chemotherapy in patients receiving first-line treatment for PDAC.